CD34+ stem cell augmentation of allogeneic, elutriated marrow grafts improves engraftment but cyclosporine A is still required to reduce GVHD and morbidity.
Noga
S J
SJ
Johns Hopkins Bone Marrow Transplantation Unit, Baltimore, Maryland, USA.
Vogelsang
G B
GB
Seber
A
A
Davis
J M
JM
Schepers
K
K
Hess
A D
AD
Jones
R J
RJ
D000328:Adult; D015703:Antigens, CD; D018952:Antigens, CD34; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002469:Cell Separation; D003114:Colony-Forming Units Assay; D016572:Cyclosporine / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008875:Middle Aged; D009017:Morbidity; D009190:Myelodysplastic Syndromes / Q000628:therapy; D018579:Patient Selection; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D014184:Transplantation, Homologous
D015703:Antigens, CD; D018952:Antigens, CD34; D007166:Immunosuppressive Agents; D016572:Cyclosporine